Abstract 9P
Background
Tissue-resident memory (TRM) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome in solid cancer patients. Liver metastases exhibit a highly immunosuppressive tumor microenvironment, however, the role and clinical impact of TRM cells infiltration in colorectal cancer remains elusive.
Methods
An exhaustive profiling was conducted on tumor-infiltrating lymphocytes isolated from 27 patients’ colorectal cancer (CRC) liver metastases. Cytokine production was evaluated in in vitro-activated TRM and non-TRM cells. 3D spheroid models were also used to study CXCR6+/- TRM cells cytotoxicity. Prognostic value of TRM cells was assessed. Single-cell RNAseq data were analyzed to investigate the transcriptomic profile of TRM cells subsets.
Results
Our analyses showed that only infiltration with CD103+CD69+ TRM cells was predictive of recurrence-free survival (RFS). However, CXCR6 expression on this TRM subset helped to stratify this population’s prognostic impact and was associated with shorter RFS. CXCR6 expression was inversely correlated to PD-1, HLA-DR, and CD39 expression, three well-validated biomarkers of tumor-reactive T cells. Strikingly, the expression of PD-1 in this TRM population was associated with improved patients’ prognosis. Interestingly, both in vitro and single-cell RNAseq data analyses revealed that CXCR6-PD1+ TRM cells showed significantly lower levels of TIM3 and LAG3 expression compared to CXCR6+PD1- that could be explained by a non-terminal exhausted state. Although both TRM populations presented high production levels of IFNg, GZMB, and IL-2; CXCR6-PD1+ TRM cells produced higher levels of TNFa. We next assessed TCF1 and TOX expression. Interestingly, CXCR6+PD1- TRM cells were more TCF1-TOX+, contrarily to CXCR6-PD1+ TRM cells that were more stem-like ‘TCF1-TOX+’. Finally, CXCR6-PD1+ TRM cells showed a significant increase in Ki67 expression.
Conclusions
We identified a novel population of TRM cells CXCR6-PD1+ that exhibit a ‘stem-like’ phenotype with higher proliferation capacity and are associated with improved prognosis in metastatic CRC patients.
Legal entity responsible for the study
UMR RIGHT 1098.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract